In late-stage colorectal adenocarcinoma, the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGFR, improved outcomes for patients with WT KRAS but not with KRAS mutations [139,140,141,142,143]; these anti-EGFR therapies are FDA approved for first-line treatment for patients with WT KRAS colorectal cancers where they used in combination with conventional chemotherapy [144]. Here, EGFR is linked to colorectal adenocarcinoma.